Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

Roussel, Murielle; Hébraud, Benjamin; Hulin, Cyrille; Perrot, Aurore; Caillot, Denis; Stoppa, Anne‐Marie; Macro, Margaret; Escoffre, Martine; Arnulf, Bertrand; Belhadj, Karim; Karlin, Lionel; Garderet, Laurent; Façon, Thierry; Guo, Shien; Weng, Josh; Dhanasiri, Sujith; Leleu, Xavier; Moreau, Philippe; Attal, Michel

doi:10.1080/10428194.2020.1719091

Cited by 24 publications

(21 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14,15 Roussel, et al studied QOL recovery in patients with newly diagnosed MM treated with induction chemotherapy with lenalidomide/ bortezomib/dexamethasone followed by AHCT or induction alone, with both groups receiving lenalidomide maintenance for 1 year. 16 This study had a similar mean age at baseline (56. the shorter time of maintenance lenalidomide. Our analysis showed that overall QOL trajectories are similar to those described by Roussel, et al and remain stable with longer time on maintenance.…”

Section: Discussionmentioning

confidence: 93%

Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma

et al. 2022

View full text Add to dashboard Cite

Early autologous hematopoietic cell transplantation (AHCT) with post‐transplant maintenance therapy is standard of care in multiple myeloma (MM). While short‐term quality of life (QOL) deterioration after AHCT is known, the long‐term trajectories and symptom burden after transplantation are largely unknown. Toward this goal, a secondary analysis of QOL data of the BMT CTN 0702, a randomized controlled trial comparing outcomes of three treatment interventions after a single AHCT (N = 758), was conducted. FACT‐BMT scores up to 4 years post‐AHCT were analyzed. Symptom burden was studied using responses to 17 individual symptoms dichotomized as ‘none/mild’ for scores 0–2 and ‘moderate/severe’ for scores of 3 or 4. Patients with no moderate/severe symptom ratings were considered to have low symptom burden at 1‐year. Mean age at enrollment was 55.5 years with 17% African Americans. Median follow‐up was 6 years (range, 0.4–8.5 years). FACT‐BMT scores improved between enrollment and 1‐year and remained stable thereafter. Low symptom burden was reported by 27% of patients at baseline, 38% at 1‐year, and 32% at 4 years post‐AHCT. Predictors of low symptom burden at 1‐year included low symptom burden at baseline: OR 2.7 (1.8–4.1), p < 0.0001; older age: OR 2.1 (1.3–3.2), p = 0.0007; and was related to being employed: OR 2.1 (1.4–3.2), p = 0.0004). We conclude that MM survivors who achieve disease control after AHCT have excellent recovery of FACT‐BMT and subscale scores to population norms by 1‐year post‐transplant, though many patients continue to report moderate to severe severity in some symptoms at 1‐year and beyond.

show abstract

Section: Discussionmentioning

confidence: 93%

Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The results of the IFM 2009 clinical trial suggest that induction and ASCT followed by maintenance provide improvement in quality of life for NDMM patients. (32) Therefore, it is important to weigh the benefit of prolonged maintenance therapy against the cost of therapy, risk of toxicity and adverse effects. Disease heterogeneity may be an additional consideration in treatment decision-making.…”

Section: Discussionmentioning

confidence: 99%

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma

Patel

Shah

Liu

et al. 2022

Clinical Cancer Research

View full text Add to dashboard Cite

The current recommended treatment for newly-diagnosed multiple myeloma involves induction treatment with a triplet or quadruplet regimen such as lenalidomide-bortezomibdexamethasone, followed by ASCT and maintenance therapy. While this approach offers improved PFS and quality of life, it is non-curative for most patients. Currently, maintenance therapy with lenalidomide post ASCT is recommended, as this has been observed to improve outcomes after ASCT. In this study, we evaluated the combination of lenalidomide and ixazomib as an all oral maintenance therapy to determine whether it would further improve clinical response in myeloma patients after ASCT, without significantly increasing toxicity. Our results demonstrate a better than expected PFS and suggest that myeloma patients may benefit further with combination maintenance therapy.Research.

show abstract

“…Interestingly, patients who experienced fewer adverse effects had a longer PFS and OS [58]. As regards the effect of timing of transplant on QoL, similar outcomes were observed in upfront and delayed ASCT groups following VRd induction [59].…”

Section: Other Considerations With Asctmentioning

confidence: 63%

Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT

Garderet

Morris

Beksaç

et al. 2020

Biology of Blood and Marrow Transplantation

Self Cite

View full text Add to dashboard Cite

Melphalan at a myeloablative dose followed by autologous stem cell transplantation (ASCT) remains the standard of care for transplant-eligible patients with myeloma. However, therapies such as new immunomodulatory drugs and proteasome inhibitors and, more recently, monoclonal antibodies and chimeric antigen receptor T cells are challenging the traditional role of ASCT. Which patients benefit from ASCT? Can its use be delayed until first relapse? The field is moving rapidly as novel agents lead to new patient care strategies. The place of ASCT in this changing landscape will be reviewed and reassessed.

show abstract

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

Cited by 24 publications

References 35 publications

Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma

Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma

Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT

Contact Info

Product

Resources

About